BBIOBridgeBio Pharma, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+11% of shares).
Rangebound, no clear trend. Price is −11% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How BBIO is trading
BridgeBio Pharma, Inc. is +25% over the past year while the S&P 500 is +18%: 6.5 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −11%
vs 200-day average · a clear downtrend
- RSI (14)
- 46
RSI (14) · neutral
- Below its 52-week high
- 24%
Below its 52-week high
Details›
- Last close2026-10-09
- $65.35
- 1 monthS&P 500 +2.7%
- −9.9%
- 1 yearS&P 500 +18%
- +25%
- 5 yearsS&P 500 +88%
- +34%
- vs 50-day average$74.74
- −13%
- 52-week high
- $85.86
- 52-week low
- $49.00
- Annualised volatility
- 52%
| Year | Return |
|---|---|
| 2026 (year to date) | −15% |
| 2025 | +179% |
| 2024 | −32% |
| 2023 | +430% |
| 2022 | −54% |
| 2021 | −77% |
| 2020 | +103% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 7 | 3 of 7 | −4.3% |
| Feb | 7 | 3 of 7 | +0.96% |
| Mar | 7 | 3 of 7 | +7.8% |
| Apr | 7 | 2 of 7 | −6.8% |
| May | 7 | 2 of 7 | −3.8% |
| Jun | 7 | 6 of 7 | +13% |
| Jul | 8 | 5 of 8 | +15% |
| Aug | 8 | 5 of 8 | +2.1% |
| Sep | 8 | 2 of 8 | −6.2% |
| Oct | 8 | 5 of 8 | +3.6% |
| Nov | 7 | 5 of 7 | +10% |
| Dec | 7 | 5 of 7 | +4.7% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.